Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2024—Qiagen has expanded its master collaboration agreement with AstraZeneca to develop and commercialize companion diagnostics for therapies being developed by AstraZeneca to address chronic diseases.
November 2024—T2 Biosystems announced FDA clearance of its T2Candida panel for pediatric patients.
November 2024—Verichem Laboratories offers multianalyte, multilevel, and liquid-stable Matrix Plus chemistry reference materials for the calibration verification of chemistry assays.
November 2024—Maine Molecular Quality Controls has launched reference materials for the Cepheid Xpert PML-RARA assay.
November 2024—Randox now offers Olink dual-antibody recognition and proximity extension assay (PEA) technology, bringing the Olink Explore, Target, and Flex panels in-house to accelerate highly specific multiplex biomarker screening.
November 2024—Illumina has unveiled its MiSeq i100 series of sequencing systems, the MiSeq i100 and MiSeq i100 Plus.
November 2024—Biofidelity announced the launch of its Aspyre Lung reagents for liquid biopsy samples. Aspyre Lung identifies established non-small cell lung cancer biomarkers in DNA and RNA from tissue and blood in a single, four-step workflow and runs on existing qPCR platforms.
November 2024—Pillar Biosciences has announced the global launch of OncoReveal Nexus, a research use only next-generation sequencing kit designed to assess key driver genes for hematological and solid tumor malignancies in one multiplex reaction.
October 2024—Thermo Fisher Scientific announced it received FDA 510(k) clearance to market its Optilite Freelite assays for the evaluation of monoclonal gammopathy of undetermined significance. The assays measure kappa and lambda free light chains in serum, enabling the identification of even small concentrations of monoclonal FLC proteins undetectable by serum protein electrophoresis.
October 2024—Smart In Media announced an AI enhancement to its PathoZoom LiveView microscope camera and software. This system incorporates “AI on the fly,” which allows users to run AI routines from their own microscope. Users select a region of interest in the field of view and AI results are returned in a few seconds. PDL-1, Ki67, ER, and PR are available now on Smart In Media’s AI menu.
